Christopher Yasiejko
Correspondents at Bloomberg News
Patents/®️/©️, IP@BLaw. Past: @business, @nytimes, @delawareonline. Bylines: @PhillyInquirer, @PhillyDailyNews, @CJR, +. Views=mine. RT≠endorsement. Tips? DM.
Articles
-
4 days ago |
news.bloomberglaw.com | Christopher Yasiejko
June 23, 2025, 8:15 PM UTC Christopher Yasiejko Senior correspondent UTC and Liquidia opened a bench trial Monday in a patent-infringement lawsuit targeting Liquidia's Yutrepia, which competes with UTC's Tyvaso, a treatment for pulmonary hypertension. Photographer: Chris Ryan/Getty Images UTC cites clinical trial as breakthrough meriting patent protectionLiquidia argues doctors used Tyvaso off-label years earlierUnited Therapeutics Corp.
-
2 weeks ago |
news.bloombergtax.com | Christopher Yasiejko
Railware Inc. and the Southeastern Pennsylvania Transportation Authority paused their lawsuit over patented railworker safety tech while they finalize a settlement agreement, according to a federal court order.
-
2 weeks ago |
news.bloomberglaw.com | Christopher Yasiejko
Railware Inc. and the Southeastern Pennsylvania Transportation Authority paused their lawsuit over patented railworker safety tech while they finalize a settlement agreement, according to a federal court order.
-
2 weeks ago |
news.bloombergtax.com | Christopher Yasiejko
MSN Laboratories Pvt. Ltd. accused Novartis AG of trying to to strong-arm a Delaware judge into ruling on its bid to block MSN’s copy of the heart-disease drug Entresto before a July 15 pediatric exclusivity deadline. Novartis’ June 9 motion for injunctive relief “essentially re-packages its post-trial brief” and relies on “voluminous” new materials while demanding a rushed response, according to a letter to Judge Richard G.
-
2 weeks ago |
news.bloomberglaw.com | Christopher Yasiejko
June 11, 2025, 4:15 PM UTC Christopher Yasiejko Senior correspondent Novartis AG signage on the floor of the New York Stock Exchange on Dec. 31, 2024. Photographer: Michael Nagle/Bloomberg Novartis ‘has gall’ to demand quick response to 200-page briefFDA’s approval timing could delay MSN’s generic till late 2026MSN Laboratories Pvt. Ltd.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 688
- Tweets
- 2K
- DMs Open
- Yes
Import 300K bottles of generic Entresto in August & 2,200 kg of the blockbuster heart-failure drug’s active ingredient in December, and what do you get? A @Novartis suit seeking damages for @MSNLabs' alleged infringement of a recently revived patent. https://t.co/EaQPvBdVPw
Thanks for the shout-out, @cmorten2! And thanks to Chris Morten (of @ColumbiaLaw), @PrEP4AllNow, @TAGTeam_Tweets & @reshmagar, each of whom shared time and energy discussing the basis for their perspectives on @HHSGov's settlement last week w/ @GileadSciences on PrEP drugs.
From the SIGN HERE; NO, REALLY Dept.🖋️: @AstellasUS can’t enforce a patent-infringement settlement with @MSNLabs over a generic version of the overactive-bladder drug Myrbetriq because the deal was never signed, a federal judge ruled. https://t.co/EQ6L9PvNg0